Quince Stockholders Approve Series C Conversion, Authorized Share Increase, and New Equity Plans
QNCX sits 78% above its 52-week low of $15.1.
Summary
Quince Therapeutics stockholders approved the Series C Preferred Stock conversion, an increase in authorized common shares to 275 million, and new 2026 equity incentive and employee stock purchase plans at the October 6 special meeting.
Key Events · Corporate Governance and Compliance · QNCX
-
Series C Conversion Approved
Stockholders approved Proposal 1 (180,550 votes for) and Proposal 2 (343,517 votes for) to issue common shares upon conversion of Series C Preferred Stock and exercise of related warrants and options.
-
Authorized Shares Increased to 275M
Proposal 3 passed with 599,460 votes for, increasing authorized common stock from 250,000,000 to 275,000,000; the Certificate of Amendment was filed and effective October 6, 2026.
-
New Equity Plans Approved
The 2026 Equity Incentive Plan (initial reserve of 821,872 shares plus up to 1,377,845 returning shares) and 2026 Employee Stock Purchase Plan (initial reserve of 142,045 shares) were approved.
-
Going Concern and Delisting Context
The approvals come as the company faces a Nasdaq delisting notice for negative stockholders' equity of $35.3 million and has disclosed substantial doubt about its ability to continue as a going concern.
Analysis · QNCX · Life Sciences
At the October 6 special meeting, Quince Therapeutics stockholders approved all five proposals, including the conversion of Series C Preferred Stock into common shares, an increase in authorized common stock from 250 million to 275 million, and new equity incentive and employee stock purchase plans. These approvals clear the path for the Orphai acquisition-related share issuances and provide the company with additional authorized shares and equity compensation capacity. The vote carries added weight because the company is under a Nasdaq delisting notice for negative stockholders' equity and has disclosed substantial doubt about its ability to continue as a going concern; the approved conversions and share reserve increases are part of its effort to address capital structure and retain talent.
How filings like this one have moved
In the 30 days to Oct 6, 2026, 28.9% of the 1573 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNCX was trading at $26.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.3M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.